Reply to: Use of induction chemotherapy in locally advanced rectal cancers to increase the response rates: Is it actually helping?

Citation for published version (APA):

Document status and date:
Published: 01/09/2021

DOI:
10.1016/j.ejso.2021.06.021

Document Version:
Publisher's PDF, also known as Version of record

Document license:
Taverne

Please check the document version of this publication:

• A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record.
• People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page numbers.

Link to publication

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain.
• You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above, please follow below link for the End User Agreement:
www.umlib.nl/taverne-license

Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.

Download date: 16 Sep. 2023
Reply to: Use of induction chemotherapy in locally advanced rectal cancers to increase the response rates: Is it actually helping?

Keywords:
Locally advanced rectal cancer
Induction chemotherapy
Chemoradiotherapy
Total neoadjuvant therapy
Pathological complete response
Clinical complete response

We thank Patel et al. for their comments to our recent manuscript. Although the results of our case-control matched study suggest that the addition of induction chemotherapy to neoadjuvant chemoradiotherapy in patients with prognostically poor LARC results in a higher CR rate than neoadjuvant chemoradiotherapy alone, we recognise that selection bias may have been present. Therefore, we acknowledge in our conclusion that no definitive recommendations can be made and further research is necessary.

The age distribution in our cohort is indeed elderly, which makes this cohort a true representation of the patients in our country: over 50% of patients are aged 70 years or older at the time of diagnosis in the Netherlands. This is also the case when looking to Europe and the United States of America. Although there are global differences, we feel that there is a high applicability of the results.

We agree with Patel et al. that younger patients more often present with poorly differentiated tumours. In a previous study we observed that young patients more frequently presented with signet cell carcinomas compared to older patients (2.6% versus 0.6%) [1]. Nevertheless, the presence of this unfavourable histology was rare, even in younger patients. Given the low prevalence and the small cohort we studied, we did not take the histology into account when performing our statistical analyses.

Despite the fact that matching was performed on tumour stage and MRF involvement, the extent of surgery was different between the two treatment groups with more extended surgeries in the induction chemotherapy group. This does not necessarily mean that the induction chemotherapy was not sufficient in downsizing the tumour in these patients. Generally, the resection planes are determined based on the initial tumour, i.e. the tumour before neoadjuvant treatment. Even when restating MRI shows partial fibrosis, our surgeons prefer to base their margins on the initial imaging since cutting through fibrosis holds the risk of cutting through tumour, leading to a much worse situation. Although matching on T stage and MRF was performed, possibly the tumour growth beyond the mesorectal fascia was more extensive in the group treated with induction chemotherapy, causing the more extended surgeries.

Patel et al. state that in the chemoradiotherapy group a poorer disease biology is present. We feel it is not possible to make this statement as in the induction chemotherapy group an abdomino-perineal resection and extended resection accounted for 60% of the interventions, whereas in the chemoradiotherapy group this accounted for 54%. Therefore, you may not conclude that stage of disease was different.

We agree that lateral lymph nodes are a poor prognostic factor. In the MEND-IT trial, a single-arm, prospective trial including patients with prognostically poor LARC that is currently being set up in the Netherlands, this is therefore one of the inclusion criteria.

Furthermore, the presence of MRF involvement, grade 4 mrEMVI and tumour deposits are criteria for inclusion. We await this and other studies before drawing any definitive conclusions regarding the use of induction chemotherapy in high-risk locally advanced rectal cancer.

Funding
None.

Disclosure
None.

Declaration of competing interest

The authors whose names are listed immediately below certify that they have NO affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.

Reference

E.L.K. Voogt, D.P. Schaap, K. van den Berg et al.

Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands

K. van den Berg
Department of Medical Oncology, Catharina Hospital, Eindhoven, the Netherlands

G.A.P. Nieuwenhuijzen, J.G. Bloemen
Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands

G.J. Creemers, J. Willems
Department of Medical Oncology, Catharina Hospital, Eindhoven, the Netherlands

J.S. Cnossen, H.M.U. Peulen
Department of Radiation Oncology, Catharina Hospital, Eindhoven, the Netherlands

J. Nederend
Department of Radiology, Catharina Hospital, Eindhoven, the Netherlands

G. van Lijnschoten
Pathology Department, PAMM Laboratory for Pathology and Medical Microbiology, Eindhoven, the Netherlands

J.W.A. Burger
Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands

H.J.T. Rutten
Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands

GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, the Netherlands

* Corresponding author. Department of Surgery, Catharina Hospital, Eindhoven, Michelangelolaan 2, 5623 EJ, Eindhoven, the Netherlands.

E-mail address: eva.voogt@catharinziekenhuis.nl (E.L.K. Voogt).

17 June 2021
Available online 24 June 2021